Designing a new sustainable Test Kit supply chain network utilizing Internet of Things

Navaei, Ali; Taleizadeh, Ata Allah; Goodarzian, Fariba

doi:10.1016/j.engappai.2023.106585

Cited by 11 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37,38 Health experts and local policymakers could build further on this experience and develop flexible strategies while preparing for future public health emergencies. 39 While several LMICs have opted to innovate and improved their research credentials during SARS-CoV-2, 37,40 sustaining it would require better understanding of Good Clinical Practices (GCP) under the given sociocultural context. 41 Future scholarship under health emergencies should focus on addressing the various barriers and facilitators to adoption and interconnectedness of GCP at institutional, legislative, and regulatory tiers.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial

Azhar,

Akram,

Latif

et al. 2024

Pak J Med Sci

View full text Add to dashboard Cite

Objective: We assessed the effectiveness of oral Hydroxychloroquine (HC), Azithromycin (AZ) and Oseltamivir (OS), alone or combined, among patients hospitalized with mildly symptomatic coronavirus infectious disease (COVID-19). Methods: Following the approval of the National Bioethics Committee and prospective registration (clinicaltrials.gov NCT04338698), a multicenter randomized clinical trial of adaptive design was conducted at 10 multispecialty hospitals in Pakistan. Patients were randomized into seven treatment groups. Starting April 15, 2020, consenting, eligible, otherwise healthy adult patients or those with co-morbidities under control, were recruited if they presented with mildly symptomatic COVID-19 (scored 3 on a 7-point ordinal scale anchored between 1 = not hospitalized, able to undertake normal activities, to 7 = death) confirmed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Two primary outcomes were assessed by day seven: Turning qRT-PCR negative; and clinical improvement of two points from the baseline. Outcome rates were compared using a chi-square test. Multiple imputations were applied to handle missing data. An interim data analysis was carried out on July 19, 2020, following which the study continued without treatment group changes. Data Safety and Monitoring Board advised to stop recruitment due to its futility on January 18, 2021. Results: Of 471 patients randomized, a total of 426 (90.4%) completed the follow-up for primary outcomes. Based on imputed data analyses at day seven: Total qRT-PCR negative cases were 137/471 (29%, 95% CI 25.0 - 33.4). By day seven, a total of 111/471 (23.5%, 95% CI 19.8 - 27.6) showed clinical improvement. No serious or non-serious adverse event was reported. Conclusions: Among patients with mild COVID-19, there was no statistically significant difference in the effectiveness of oral antimalarial, antiviral, or antibiotic treatments. Clinicaltrials.gov ID: NCT04338698. doi: https://doi.org/10.12669/pjms.40.5.8757 How to cite this: Azhar S, Akram J, Latif W, Ibanez NC, Mumtaz S, Rafi A, et al. Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial. Pak J Med Sci. 2024;40(5):---------. doi: https://doi.org/10.12669/pjms.40.5.8757 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract